Transthyretin Amyloidosis (ATTR)
American College of Cardiology (ACC) 2025
Congress Details
29-31 March, 2025 | USA
Chicago, IL, USA
The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
Congress Materials
Presentation Type
Location
Title
Presentation Type
Location
Title
Presentation Type
Location
Title
Associated Materials
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study
Annals of Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial
Nature Medicine
